Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - brexucabtagene autoleucel, quantity: 1000000 cells/kg - injection, intravenous infusion - excipient ingredients: dimethyl sulfoxide; sodium chloride; albumin - cellular therapies - tecartus is a genetically modified autologous immunocellular therapy for the treatment of patients greater than or equal to 18 years of age with relapsed or refractory (r/r) b-cell acute lymphoblastic leukaemia (b-all).

Καναδάς - Αγγλικά - Health Canada

gilead sciences canada inc - brexucabtagene autoleucel - suspension - 100000000cells - brexucabtagene autoleucel 100000000cells

Νότια Αφρική - Αγγλικά - South African Health Products Regulatory Authority (SAHPRA)

cipla medpro (pty) ltd - capsules - 100,0 mg - each capsule contains acalabrutinib 100,0 mg